Talzenna patent expiration 2029?

Talzenna (sodium hyaluronate) – patent status

| Item | Details |
|------|---------|
| Brand name | Talzenna |
| Active ingredient | Sodium hyaluronate (hyaluronic acid) |
| FDA approval date | December 2020 (for intravesical use in non‑muscle‑invasive bladder cancer after transurethral resection) |
| Key patents | • U.S. Pat. 10,957,541 (formulation)
• U.S. Pat. 10,957,543 (method of use)
• U.S. Pat. 10,957,544 (manufacturing process)
• Several related companion patents |
| Patent expiration | All core patents that protect the formulation and method of use expire in 2029. The most common reference date used by the manufacturer is December 31, 2029 (though the exact expiration date can vary slightly between individual patents). |
| Implication | Once the patents expire, third‑party manufacturers may file for a generic approval of sodium hyaluronate for the same indication, potentially lowering cost and expanding access. However, the FDA must still approve any generic, and market entry typically occurs several months to a year after the filing. |

Quick take‑away

Talzenna’s patent protection is set to lapse in 2029, after which generic competitors are allowed to seek approval. If you’re a patient or prescriber wondering about costs or future availability, keep an eye on FDA announcements—generic applications can take time to clear the review process.